Loading…
ACIU
AC Immune SA
NASDAQ· Healthcare· Biotechnology· CUSIP H00263105
$2.73+2.82%Price as of Sep 22, 22:36 UTC · updated once a day, after the close
Key metrics
- Market cap
- $271.44M
- P/E
- —
- Forward P/E
- 4.5x
- P/B
- 6.3x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.52
- ROE
- -78.53%
- Profit margin
- -246.48%
- Revenue growth
- +1057.20%
- Beta
- 1.59
- 52-week high
- $4.00
- 52-week low
- $2.10
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -60.9% over 5Y.
today you would have $375.56▼ -62.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $3.14 | $2.70 | $5.00 | $2.04 | |
| P/S | 38.4x | 89.4x | 9.9x | 33.5x | 43.4x |
| P/B | 2.8x | 7.1x | 2.4x | 3.1x | 1.0x |
| EPS | -$0.70 | -$0.51 | -$0.64 | -$0.85 | |
| Profit margin | -1082.23% | -1971.65% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TRDAEntrada Therapeutics, Inc. | $7.00 | — | 0.9x | — | -54.09% | $272.56M |
| ANIKAnika Therapeutics, Inc. | $20.38 | — | 2.0x | — | -2.19% | $272.68M |
| LYELLyell Immunopharma, Inc. | $11.15 | — | 1.1x | — | -93.28% | $273.23M |
| PYXSPyxis Oncology, Inc. | $3.23 |
About the company
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
- 90
- Lausanne, Switzerland
Company description provided by Yahoo Finance.